Overview

A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
This is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, flexible dose titration, the third period is a placebo-controlled withdrawal comparing MCI-196 with placebo for 4 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Corporation